Literature DB >> 1580153

Long-term treatment in infantile choriocarcinoma.

T Hongo1, Y Fujii, T Fukuoka, S Iijima, T Matsusita, Y Nakagawa, Y Igarashi.   

Abstract

The long-term treatment of a 5 month old boy with precocious puberty secondary to the production of chorionic gonadotropin (hCG) by a choriocarcinoma is described. Of 13 cases of infantile choriocarcinoma reported in the literature, none were successfully treated. The present study describes a partially successful outcome with embolization of a hepatic tumor, irradiation of lung and right submandibular tumors, chemotherapy with methotrexate (MTX), actinomycin D (ACD), cyclophosphamide (CPA) and etoposide (VP16), and splenectomy and hepatic lobectomy. Subsequently, the residual hepatic tumors were treated with high dose melphalan (HDM) followed by reinfusion of unpurged autologous marrow.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580153     DOI: 10.1111/j.1442-200x.1992.tb00925.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN: 0374-5600


  4 in total

1.  Infantile choriocarcinoma: a case report with MRI, angiography and bone scintigraphy.

Authors:  R Sashi; K Sato; H Hirano; N Tomura; J Watarai; A Ishida; M Morita
Journal:  Pediatr Radiol       Date:  1996-12

2.  Primary intracranial choriocarcinoma: MR imaging findings.

Authors:  X-F Lv; Y-W Qiu; X-L Zhang; L-J Han; S-J Qiu; W Xiong; G Wen; Y-Z Zhang; J Zhang
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-08       Impact factor: 3.825

Review 3.  Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review.

Authors:  Martin E G Blohm; Ulrich Göbel
Journal:  Eur J Pediatr       Date:  2003-11-20       Impact factor: 3.183

4.  Simultaneous Occurrence of Choriocarcinoma in an Infant and Mother.

Authors:  Małgorzata Rzanny-Owczarzak; Joanna Sawicka-Metkowska; Katarzyna Jończyk-Potoczna; Ewelina Gowin; Patrycja Sosnowska-Sienkiewicz; Przemysław Mańkowski; Danuta Januszkiewicz-Lewandowska
Journal:  Int J Environ Res Public Health       Date:  2021-02-17       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.